Title: Stabilized FGF Formulations Containing Reducing Agents Invertor(s): Robert V. Hageman, Bret A. Shirley, Kamaljit K. Pation No: Not yet assigned Att. No: PP16021.002 (35784/213736)

Liquid rFGF-2 Formulations CN-RP-HPLC % Main Peak 4°C




Figure 1

Title: Stabilized FGF Formulations Containing Reducing Agents Insentor(s): Robert V. Hageman, Bret A. Shirley, Kamaljit K. Cation No: Not yet assigned

Any Dkt No: PP16021.002 (35784/213736)

rFGF-2 Liquid Formulations CN-RP-HPLC % Main Peak 17°C




Figure 2

Title: Stabilized FGF Formulations Containing Reducing Agents Inventor(s): Robert V. Hageman, Bret A. Shirley, Kamaljit K. Bajwa

Application No: Not yet assigned Atty Dkt No: PP16021.002 (35784/213736) CN-RP-HPLC % Main Peak 30°C





Figure 3

Limid rFGF-2 Formulations % Main Peak CN-RP-HPLC 30°C




- 0 mM Acetyl Cysteine / 0 mM DTT pH 5.5
- .. . 0.5% Acetyl Cysteine pH 5.5
- --▲- 10 mM DTT pH 5.5
- -₩ 0.5% Acetyl Cysteine / 10 mM DTT pH 5.5
- 0.5% Acetyl Cysteine pH 6.0
- _O 10 mM DTT pH 6.0
- 0.5% Acetyl Cysteine / 10 mM DTT pH 6.0
- -∆- 0.5% Acetyl Cysteine pH 6.5
- 0.5% Acetyl Cysteine / 10 mM DTT pH 6.5

Days

Figure 4

Title: Stabilized FGF Formulations Containing Reducing Agents Inventor(s): Robert V. Hageman, Bret A. Shirley, Kamaljit K. Bajwa Application No: Not yet assigned Atty Dkt No: PP16021.002 (35784/213736)

Lyoph ized rFGF-2 Formulations CN-RP-HPLC % Main Peak 40°C



- 0% Acetyl Cysteine / 0 mM DTT pH 5.5
- 0.5% Acetyl Cysteine pH 5.5
- ____ 10 mM DTT pH 5.5

- 0.5% Acetyl Cysteine / 10 mM DTT pH 5.5
- • 0.5% Acetyl Cysteine pH 6.0
- -O 10 mM DTT pH 6.0


- -<>→ 10 mM DTT pH 6.5
- 0.5% Acetyl Cysteine / 10 mM DTT pH 6.5

Figure 5

All formulations contain:

10 mM sodium citrate 2% glycine 1% sucrose 1 mM EDTA Title: Stabilized FGF Formulations Containing Reducing Agents Inventor(s): Robert V. Hageman, Bret A. Shirley, Kamaljit K. Bajwa Application No: Not yet assigned Atty Dkt No: PP16021.002 (35784/213736)

Lyophilized rFGF-2 Formulations CN-RP-HPLC % Main Peak 50°C





- 0.5% Acetyl Cysteine pH 5.5
- _▲ 10 mM DTT pH 5.5
- 0.5% Acetyl Cysteine / 10 mM DTT pH 5.5
- 0.5% Acetyl Cysteine pH 6.0
- -_O 10 mM DTT pH 6.0
- -_ 0.5% Acetyl Cysteine / 10 mM DTT pH 6.0
- -∆- 0.5% Acetyl Cysteine pH 6.5
- -√- 10 mM DTT pH 6.5
 - 5 0.5% Acetyl Cysteine / 10 mM DTT pH 6.5

Weeks

Figure 6

All formulations contain:

10 mM sodium citrate 2% glycine 1% sucrose 1 mM EDTA Title: Stabilized FGF Formulations Containing Reducing Agents Inventor(s): Robert V. Hageman, Bret A. Shirley, Kamaljit K. Bajwa Application No: Vot yet assigned
Ary Dist No: PD16071 002 (357847) 3336)

Atty Dkt No: PP16021.002 (35784/213736)

rhFGF2 Stability 30°C RP-HPLC % Main Peak

